Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma's Chairman and Chief Executive Officer, Raymond W Urbanski MD, PhD, Provides Further Insight into the Recent Activity in the Natural Killer Cell (NK) Space
Oct 4, 2018 • 9:05 EDT | Read More

GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors
Sep 13, 2018 • 8:36 EDT | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range